

WHAT IS CLAIMED:

1. A substantially pure human fibroblast growth factor receptor capable of binding human FGF.
2. The fibroblast growth factor receptor of claim 1, wherein said fibroblast growth factor receptor has substantially the amino acid sequence shown in Figure 2.
3. A substantially pure recombinant human fibroblast growth factor receptor (rFGF-R) capable of binding FGF.
4. The rFGF-R of claim 3 having substantially the amino acid sequence shown in Figure 2.
5. The rFGF-R of claim 3 comprising amino acids 1-374 of the amino acid sequence shown in Figure 2.
6. A method for inhibiting the activity of FGF on a cell, said method comprising providing an effective amount of FGF-R to the cell.
7. The method of claim 6, wherein said cell is cultivated in vitro.
8. The method of claim 6 wherein said FGF-R is provided by administration to a mammal.
9. The method of claim 6, wherein said FGF-R is recombinant.

10. The method of claim 9, wherein said recombinant FGF-R is soluble and comprises amino acids 1-374 of the amino acid sequence shown in Figure 2.

5 11. The method of claim 6, wherein said cell is an FGF-dependent tumor cell.

12. The method of claim 6, wherein said activity of FGF on a cell is angiogenesis.

10 13. A method for inhibiting infection of a mammal by a Herpes virus, comprising:
administering to said mammal an effective amount of rFGF-R.

15 14. The method of claim 13, wherein said rFGF-R is sFGF-R.

20 15. The method of claim 14, wherein said sFGF-R is sFGF-R₁₋₃₇₄.

16. The method of claim 13, wherein said rFGF-R is administered to the mucosal membranes of said mammal.

25 17. The method of claim 16, wherein said rFGF-R is administered as an aerosol.

providing a rFGF-R;

detecting the occurrence of specific binding between bound and rFGF-R.

20. The method of claim 18, wherein specific is determined by competition with labeled FGF.

21. The method of claim 18, wherein specific binding is determined spectroscopically.